Rockefeller Capital Management
STOK icon

Rockefeller Capital Management’s Stoke Therapeutics STOK Stock Holding History

Rockefeller Capital Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$12.5K Hold
481
– – ﹤0.01% 4082
2026
Q2 		$15.7K Hold
481
– – ﹤0.01% 3824
2026
Q1 		$15.7K Buy
481
+383
+391% +$12.6K ﹤0.01% 3804
2025
Q4 		$3.11K Buy
+98
New +$2.95K ﹤0.01% 4207

Other funds holding STOK

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Rockefeller Capital Management's STOK Position: Q3 2026 in Review

Rockefeller Capital Management held its Stoke Therapeutics (STOK) position steady in Q3 2026 at 481 shares worth $12.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4082.

Rockefeller Capital Management first reported a position in STOK in Q4 2025 and has held it in 4 quarters since. The position peaked at $15.7K in Q2 2026. 120 funds tracked by Wall St. Rank hold STOK as of Q3 2026.

  • Rockefeller Capital Management held 481 shares of Stoke Therapeutics worth $12.5K as of Q3 2026.
  • Rockefeller Capital Management left its Stoke Therapeutics share count unchanged in Q3 2026.
  • Stoke Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #4082 holding.
  • Rockefeller Capital Management first reported a position in Stoke Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Rockefeller Capital Management's Stoke Therapeutics position peaked at $15.7K in Q2 2026.
  • 120 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.